Introduction/Background Reccurrent epithelial ovarian cancer progressing after multiple lines of chemotherapy usually show a deterioration of PS & poor chemotolerance so giving them further chemo maintaing dose density is a problem.Hence they were given low dose continuous oral chemo (OMCT).

Methodology Retrospective observational study. Data of cases of receiving OMCTafter multiple lines of chemotherapy failure were procured from medical oncology & gyne-oncology OPD records in between 2019 Jan& 2022 Jan.The OMCT was composed of oral cyclophosphamide 25 mg, etoposide 25 mg, tamoxifen20 mg daily. CBC was checked monthly. Later on Progression Free Survival (PFS) & Overall Response Rate was calculated.Quality of life (QOL)was calculated monthly.

Results The median PFS was 4 months (3 mon–5 mon).The median ORR was 15% (13%-17%).Commonest toxicity was grade 2 anaemia. No grade 3 toxicity.There were 10 deaths all secondary to disease progression.Among QOL pain & vomiting improved most.

Conclusion OMCT is quite effective least toxic therapy in heavily treated progressive ovarian cancer. However randomized trial required comparing it with single agent oral etoposide & best supportive care.